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EXPERIMENTAL AND RESULTS
Compound
Cell lines (IC50 mg ml
-1)a
HT-29 MCF-7 SKOV-3
Cisplatin 5.0± 0 2.4 ± 0.6 1.4 ± 0
H2L1 > 100 > 100 83.3 ± 0.8
1 > 100 > 100 72.3 ± 0.3
2 35.3 ± 0.6 6.7 ± 0.1 5.7 ± 0.1
3 34.7 ± 0.6 27.7 ± 0.3 5.6 ± 0.1
4 7.1 ± 0.3 3.6 ± 0.2 5.7 ± 0.1
5 > 100 > 100 > 100
6 > 100 > 100 > 100
H2L2 > 100 > 100 100 ± 0
7 > 100 > 100 > 100
8 8.2 ± 0.2 2.2 ± 1.2 5.6 ± 0.1
9 41 ± 1 7.9 ± 0.1 5.7 ± 0
10 4.6 ± 0.1 8.2 ± 0.2 5.4 ± 0.1
11 > 100 > 100 > 100
12 > 100 > 100 > 100
Scheme 1: Preparation of TRIS diorganotin(IV) complexes Table 1: Cytotoxic activity of TRIS ligands 
and complexes
a IC50 values (µg ml
-1) = inhibition concentration at 50% i.e., the concentration to 
reduce growth of cancer cells by 50% 
Diagram: Structures of selected TRIS diorganotin(IV) complexes
Metal complexes have been successfully used in the treatment of numerous human diseases including cancer. Among these 
metal complexes, organotin(IV) have been widely studied for their biological activities. Tris(hydroxymethyl)aminomethane
(TRIS) and its Schiff base derivatives are known to have a broad spectrum of biological activities including antitumour, 
antibiotic, anticancer, antihistamine, antifungal, anti-inflammatory, etc. In the present studies, several ligands were 
prepared by reacting TRIS with substituted salicylaldehydes. As the ligands are found to have potential biological activities,
it is our objectives to focus on the investigation of the structural features and biological properties of the prepared 
diorganotin(IV) complexes. The in vitro cytotoxic activity of the ligands and complexes had been evaluated against several 
cancer cell-lines, namely HT-29, SKOV-3 and MCF-7.
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